Moderna Inc. said Wednesday that his experimental coronavirus vaccine caused immune responses in people 56 years and older that were comparable to those seen in younger adults in a small study, a promising sign for a vulnerable age group. Older adults have a higher risk of hospitalization and death of …
Read More »
Text size Maddie Meyer / Getty Images Analysts begin to speculate on which of the Covid-19 vaccines could win, after scientists working on two of the most advanced vaccine programs made presentations about their progress at a meeting of a key advisory committee at the Centers for Disease Control and …
Read More »
The COVID-19 vaccine candidates developed by Moderna Inc. and BioNTech and Pfizer Inc. will require strict standards for cooling, and that may hinder how they are distributed to the hundreds of millions of Americans who expect to receive them. Shares of Modern MRNA, -3.54% were 3.6% lower in trading on …
Read More »
Text size Dreamstime Older adults who participated in Moderna‘s Phase 1 trial of its Covid-19 vaccine responded just as well as younger adults, according to data, the biotech company presented Wednesday morning to a key Centers for Disease Control and Prevention Advisory panel. This is important because Covid-19 is not …
Read More »